Building on a unique three-dimensional in vitro muscle model methodology developed within the Erasmus MC departments of pediatrics and clinical genetics, Myonovum, a to-be-founded Erasmus MC spin-off, will offer analysis services to pharmaceutical and biotech companies in the field of drug development for neuromuscular diseases. By doing so, Myonovum will catalyze the expedited development of improved therapies and therapeutic strategies at a reduced cost ultimately leading to radically improved care for patients.